Boryung’s Two-Track R&D Strategy: Innovative Drugs And Cash Cows
Initial Oncology Focus
Executive Summary
Boryung’s chief technology officer outlines R&D strategy to move forward as a Korea-based global pharma firm and how domestic pharmas are juggling new drug development and generating cash cows.
You may also be interested in...
Korean Biopharma Today And Tomorrow: M&A, Investment, Governance
Experts shared views at a recent conference in Seoul on how the Korean biopharma industry has evolved and what needs to be done to move forward in the next 10 years. Policy efficiency and family ownership in the sector came in for particular scrutiny, with some calling for sweeping changes.
Korea Q2 Roundup: In-House Drugs, Exports Help Hanmi, Daewoong, Boryung
Among the strong performers, Hanmi benefitted from growth for in-house-developed metabolic disease drugs and China cold syrup sales and Daewoong was boosted by exports of botulinum toxin, while Boryung reported record quarterly sales helped by its flagship antihypertensive.
APAC Regulatory Roundup: Infectious Disease A Common Theme As COVID Lingers
A roundup of key regulatory and policy developments in the Asia-Pacific in the first half of the year reveals broad developments across the region's diverse markets, although there seemed to be a common thread - a renewed focus on infectious diseases amid the lingering impact of the pandemic and the emergence of new threats.